BriaCell Therapeutics Warrant (BCTXL)

• Market cap: $1.96M
• 1 day: 0%
• 5 days: 1.43%
• 1 month: -32.05%
• 3 months: -34.59%
• 6 months: -24.74%
• Year to date: -24.74%
• 1 year: -24.74%
• 5 years: -24.74%
• 10 years: -24.74%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.

Employees: 4